NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Nov 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
ZEPBOUND (tirzepatide) by Eli Lilly and Company is g-protein-linked receptor interactions [moa]. Approved for glucose-dependent insulinotropic polypeptide receptor agonist [epc]. First approved in 2023.
Drug data last refreshed 19h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEPBOUND (tirzepatide) is a dual GIP/GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight with weight-related complications. It works by activating G-protein-linked receptors to enhance glucose-dependent insulin secretion and reduce appetite. Administered as a subcutaneous injection, it represents a new pharmacological class for obesity treatment.
Growth12.7 years to LOE
ZEPBOUND is in rapid growth phase within a market dominated by its sister product MOUNJARO; expect expanding commercial and access teams as label indications broaden.
Mechanism of Action
G-Protein-linked Receptor Interactions
Pharmacologic Class:
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Started Jan 2027
70 enrolled
Obesity
A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
Started Dec 2026
948 enrolled
Type 2 Diabetes Mellitus
Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide
Started Oct 2026
650 enrolled
ObesityType 2 Diabetes (T2D)
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
Started Oct 2026
60 enrolled
OverweightObesityType 2 Diabetes
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Started Sep 2026
150 enrolled
Obesity
Worked on ZEPBOUND at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.